This paper provides some historical aspects on the research and develo
pment of Humulin(R) (rDNA origin), the first human health-care product
derived from rDNA technology more than a decade ago. Also referred to
as biosynthetic human insulin, Humulin(R) is currently produced via t
he human proinsulin route, using an Escherichia coli fermentation proc
ess. The authenticity, high purity, and safety of BHI has been investi
gated and verified by a complex battery of analytical and physicochemi
cal methods. The daily treatment of more than two million diabetic pat
ients worldwide with this rDNA human insulin not only demonstrates the
value of rDNA technology in providing an important medical product, i
t is assurance that diabetic patients will have unlimited supplies of
this vital hormone as well as potential analogue refinements.